Presented by
In collaboration with

Date
3 & 5 March 2021

Time
13:00 - 17:45 (GMT+9)

Register now
  • About Us
  • Agenda
  • Speakers

About Us

The Healthcare Industries Division, Commerce and Service Industry Policy Group, under the Ministry of Economy, Trade and Industry (METI) of the Government of Japan, is planning focused sector-specific webinars for promoting quality and productivity in Japanese Industry in association with a Public-Private Partnership of Japan, Medical Excellence JAPAN jointly with Nomura Research Institute (NRI), and industry – Academia bodies. It will be held on March 3rd and March 5th this year.

Hospitals can look forward to learn about the ASEAN healthcare landscape from ASEAN organisation itself, Deloitte Asian healthcare expert, WHO, the ASEAN regulatory agencies and hospital associations.

 

Presented by


Ministry
METI’s mission is to develop Japan’s economy and industry by focusing on promoting economic vitality in private companies and smoothly advancing external economic relationships, and to secure stable and efficient supply of energy and mineral resources.

In collaboration with



Medical Excellence JAPAN (MEJ) is a public-private partnership, which was established to serve as the central organizational hub to facilitate overseas expansion in the healthcare and medical care sector, based on one of Japan’s growth strategies.

MEJ is an organization that promotes international health cooperation by joint with governments, medical communities, academic organizations encompassing associations of medical sciences, and the healthcare industry.




Nomura Research Institute, Ltd. (NRI) was born out of the 1988 merger between the former Nomura Research Institute, Ltd., founded in 1965 as Japan’s first fully-fledged private sector think tank, and Nomura Computer Systems Co., Ltd., which was established in 1966 and achieved the first business applications for commercial computers in Japan.

Since its inception, NRI has always been on the cutting edge. By advising policy proposals and corporate strategies or developing new systems, we have always strived to push the boundaries and explore new horizons. At NRI, we are dedicated to helping our clients manage the complexity of today’s markets with confidence.

Agenda

Japan timezone (GMT+9)

  • Day 1
  • Day 2

Wednesday, March 3

13:00 - 13:05
Opening Remarks: Ministry of Economy, Trade, and Industries
  • Takura Inamura

    Director, Healthcare industries division, Ministry of Economy, Trade and  Industry (METI), Government of Japan

    Takura Inamura Director, Healthcare industries division, Ministry of Economy, Trade and  Industry (METI), Government of Japan

    Mr. Inamura joined METI in 1998 and has mostly worked on policy-making in areas such as energy, international trade, and manufacturing industries. Before taking up his current position, he was the director in charge of a drastic revision of the Japanese legislation on the electricity supply business to enable the cost-effective deployment of renewable energy and sustainable investment in the power grid system. Holds a BA in Law from the University of Tokyo and MA from the Fletcher School of Law and Diplomacy, Tufts University.
13:05 - 13:10
Welcome Remarks: Medical Excellence Japan
  • Dr Tatsuya Kondo

    Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Dr Tatsuya Kondo Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA). As the Chief Executive of PMDA from 2008-2018, he directed all operations, including drug relief services, reviews of medical products, and post-marketing safety. He was also a significant player of ICMRA among the world's top Drug Regulatory Agencies. He has reformed all around the faculties of PMDA, basically on the three major initiatives, which are “the PMDA’s newly established Philosophy”, “Regulatory Science”, and the respect for regulatory harmonization. Prior to joining PMDA, he spent most of his career as a neurosurgeon after he graduated from the Medical Department, the University of Tokyo in 1968. He experienced not only so many kinds of neurosurgical operations but also as a surgeon-scientist so many kinds of R&D. He invented the stereotactic radiosurgery system, which synchronizes with breathing in 1992 and discovered the new FGF-9 from an operated brain tumor that has the thrombocyte growth activity in 1993. These inventions and discoveries were never implemented in society. It was because it was too early. He has been every time curious about the scientific study and the promotion of technology. Dr. Kondo has wide-ranging experience overseas, such as fellowship in Max-Planck Institute, Germany for biological research in 1977, and visiting surgeon in China-Japan Friendship Hospital, Beijing in 1987 to establish Department of Neurosurgery under JICA project. Currently, he has been serving as the Advisor on Health and Medical Strategy for the Cabinet Secretariat of the Japanese Government for six years. Moreover, he has also been an advisory member of the Center for Regulatory Authority (CoRE) of Singapore from 2014. When it comes to priorities, he expresses strong intentions about the healthcare issues he hopes multi-stakeholders will tackle, as the CEO of MEJ, he becomes a leading force of the momentum toward healthcare reform; “the fourth dimensions” revolutionary healthcare reform plan.
13:10 - 13:15
Special message: ASEAN Secretariat
13:15 - 13:45
Keynote 1: Dr. Hiroki Nakatani

A positive outlook on the resilience and diplomacy of healthcare in the ASEAN region after COVID-19.

  • Dr Hiroki Nakatani

    Project Professor, Global Research Institute at Keio University

    Dr Hiroki Nakatani Project Professor, Global Research Institute at Keio University

    In the past four years, Dr. Hiroki Nakatani has been Project Professor, Global Research Institute at Keio University and Invited Professor at Osaka University Post Graduate School of Medicine. Also, Dr. Nakatani has engaged himself with various national and international institutions as Member, Executive Board, WHO; Minister’s Advisor on International Affairs, Ministry of Health, Labour and Welfare; Chair, Board of Directors, Global Health Innovative Technology Fund (GHIT Fund); Project Director, Hub on Population Ageing, Association of Pacific Rim Universities( APRU); Member, Board of Directors, National Center for Global Health and Medicine; and Director, Human Resource Strategy Center for Global Health with grant from the Ministry. He is a veteran public health specialist over 40 years, who started his career at the Ministry of Health, Labour and Welfare. Dr Nakatani’s worked extensively in the area of health policy, public health, international health and health science and technology. Part of his national career includes assignment for Hiroshima Prefecture where he was in charge of integration of health and welfare services in preparation for rapidly coming ageing society. With regards to international career, he represented the Government at various international conferences and meetings. Dr.Nakatani served WHO Headquarters twice. First as the Policy Analysist in the Department of Human Resource for Health from April 1988 to March 1993 and recently as Assistant Director-General of WHO from March 2007 to May 2015. He led the largest technical cluster comprising HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases. During his tenure, the morbidity and mortality of these three major infections showed trends of decline, and a few tropical diseases were on track towards elimination and even eradication in case of dracunculiasis (guinea worm disease). Dr. Nakatani received his M.D. from Keio University School of Medicine, M.H.P.Ed from the University of New South Wales, and Ph.D. from Keio University.
13:45 - 14:15
Keynote 2: Mr. Ashish Mahajan

Progress of ASEAN healthcare sector despite the pandemics

14:45 - 15:00
Regulatory Session: MEJ and PMDA
15:00 - 17:45
Medical Device Regulation Updates

Effective communication w/ Industries for fast and proper access to patients

Friday, March 5

13:00 - 13:10
Opening and Welcome Remarks: Medical Excellence Japan
13:10 - 13:40
Keynote: WHO Western Pacific Reginal Office (WPRO)
13:40 - 14:10
Vietnam: Health Policy Updates 2021
14:10 - 14:40
Thai: Health Policy Updates 2021
14:40 - 14:55
Questions and Answers
15:00 - 16:00
Thai Private Hospital Association
  • Introduction (5mins)
  • Outlook into 2021 (15mins)
  • Chronic disease management (15mins)
  • Japanese medical device companies rapid fire presentations (25mins)
16:00 - 17:00
Indonesia Private Hospital Association
  • Introduction (5mins)
  • Outlook into 2021 (15mins)
  • Chronic disease management (15mins)
  • Japanese medical device companies rapid fire presentations (25mins)

Speakers


  • Takura Inamura
    Mr. Inamura joined METI in 1998 and has mostly...

    Takura Inamura Director, Healthcare industries division, Ministry of Economy, Trade and  Industry (METI), Government of Japan

    Mr. Inamura joined METI in 1998 and has mostly worked on policy-making in areas such as energy, international trade, and manufacturing industries. Before taking up his current position, he was the director in charge of a drastic revision of the Japanese legislation on the electricity supply business to enable the cost-effective deployment of renewable energy and sustainable investment in the power grid system. Holds a BA in Law from the University of Tokyo and MA from the Fletcher School of Law and Diplomacy, Tufts University.
  • Dr Tatsuya Kondo
    Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of...

    Dr Tatsuya Kondo Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA)

    Tatsuya Kondo, M.D., Ph.D., is Chief Executive Officer of Medical Excellence JAPAN (MEJ) and Chief Executive Emeritus of the Pharmaceuticals and Medical Devices Agency (PMDA). As the Chief Executive of PMDA from 2008-2018, he directed all operations, including drug relief services, reviews of medical products, and post-marketing safety. He was also a significant player of ICMRA among the world's top Drug Regulatory Agencies. He has reformed all around the faculties of PMDA, basically on the three major initiatives, which are “the PMDA’s newly established Philosophy”, “Regulatory Science”, and the respect for regulatory harmonization. Prior to joining PMDA, he spent most of his career as a neurosurgeon after he graduated from the Medical Department, the University of Tokyo in 1968. He experienced not only so many kinds of neurosurgical operations but also as a surgeon-scientist so many kinds of R&D. He invented the stereotactic radiosurgery system, which synchronizes with breathing in 1992 and discovered the new FGF-9 from an operated brain tumor that has the thrombocyte growth activity in 1993. These inventions and discoveries were never implemented in society. It was because it was too early. He has been every time curious about the scientific study and the promotion of technology. Dr. Kondo has wide-ranging experience overseas, such as fellowship in Max-Planck Institute, Germany for biological research in 1977, and visiting surgeon in China-Japan Friendship Hospital, Beijing in 1987 to establish Department of Neurosurgery under JICA project. Currently, he has been serving as the Advisor on Health and Medical Strategy for the Cabinet Secretariat of the Japanese Government for six years. Moreover, he has also been an advisory member of the Center for Regulatory Authority (CoRE) of Singapore from 2014. When it comes to priorities, he expresses strong intentions about the healthcare issues he hopes multi-stakeholders will tackle, as the CEO of MEJ, he becomes a leading force of the momentum toward healthcare reform; “the fourth dimensions” revolutionary healthcare reform plan.
  • Dr Hiroki Nakatani
    In the past four years, Dr. Hiroki Nakatani has...

    Dr Hiroki Nakatani Project Professor, Global Research Institute at Keio University

    In the past four years, Dr. Hiroki Nakatani has been Project Professor, Global Research Institute at Keio University and Invited Professor at Osaka University Post Graduate School of Medicine. Also, Dr. Nakatani has engaged himself with various national and international institutions as Member, Executive Board, WHO; Minister’s Advisor on International Affairs, Ministry of Health, Labour and Welfare; Chair, Board of Directors, Global Health Innovative Technology Fund (GHIT Fund); Project Director, Hub on Population Ageing, Association of Pacific Rim Universities( APRU); Member, Board of Directors, National Center for Global Health and Medicine; and Director, Human Resource Strategy Center for Global Health with grant from the Ministry. He is a veteran public health specialist over 40 years, who started his career at the Ministry of Health, Labour and Welfare. Dr Nakatani’s worked extensively in the area of health policy, public health, international health and health science and technology. Part of his national career includes assignment for Hiroshima Prefecture where he was in charge of integration of health and welfare services in preparation for rapidly coming ageing society. With regards to international career, he represented the Government at various international conferences and meetings. Dr.Nakatani served WHO Headquarters twice. First as the Policy Analysist in the Department of Human Resource for Health from April 1988 to March 1993 and recently as Assistant Director-General of WHO from March 2007 to May 2015. He led the largest technical cluster comprising HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases. During his tenure, the morbidity and mortality of these three major infections showed trends of decline, and a few tropical diseases were on track towards elimination and even eradication in case of dracunculiasis (guinea worm disease). Dr. Nakatani received his M.D. from Keio University School of Medicine, M.H.P.Ed from the University of New South Wales, and Ph.D. from Keio University.